Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
2010 1
2012 1
2013 1
2014 1
2015 7
2016 15
2017 14
2018 13
2019 17
2020 14
2021 19
2022 10
2023 13
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Results by year

Filters applied: . Clear all
Page 1
In Reply.
de Velasco G, Culhane AC, Heng DYC, Signoretti S, Choueiri TK. de Velasco G, et al. Oncologist. 2017 Dec;22(12):1561. doi: 10.1634/theoncologist.2017-0283. Epub 2017 Sep 11. Oncologist. 2017. PMID: 28894018 Free PMC article.
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Pal SK, Albiges L, Tomczak P, Suárez C, Voss MH, de Velasco G, Chahoud J, Mochalova A, Procopio G, Mahammedi H, Zengerling F, Kim C, Osawa T, Angel M, Gupta S, Khan O, Bergthold G, Liu B, Kalaitzidou M, Huseni M, Scheffold C, Powles T, Choueiri TK. Pal SK, et al. Among authors: de velasco g. Lancet. 2023 Jul 15;402(10397):185-195. doi: 10.1016/S0140-6736(23)00922-4. Epub 2023 Jun 5. Lancet. 2023. PMID: 37290461 Clinical Trial.
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival.
Dudani S, de Velasco G, Wells JC, Gan CL, Donskov F, Porta C, Fraccon A, Pasini F, Lee JL, Hansen A, Bjarnason GA, Beuselinck B, Pal SK, Yuasa T, Kroeger N, Kanesvaran R, Reaume MN, Canil C, Choueiri TK, Heng DYC. Dudani S, et al. Among authors: de velasco g. JAMA Netw Open. 2021 Jan 4;4(1):e2021869. doi: 10.1001/jamanetworkopen.2020.21869. JAMA Netw Open. 2021. PMID: 33475752 Free PMC article.
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors.
El Zarif T, Nassar AH, Pond GR, Zhuang TZ, Master V, Nazha B, Niglio S, Simon N, Hahn AW, Pettaway CA, Tu SM, Abdel-Wahab N, Velev M, Flippot R, Buti S, Maruzzo M, Mittra A, Gheeya J, Yang Y, Rodriguez PA, Castellano D, de Velasco G, Roviello G, Antonuzzo L, McKay RR, Vincenzi B, Cortellini A, Hui G, Drakaki A, Glover M, Khaki AR, El-Am E, Adra N, Mouhieddine TH, Patel V, Piedra A, Gernone A, Davis NB, Matthews H, Harrison MR, Kanesvaran R, Giudice GC, Barata P, Farolfi A, Lee JL, Milowsky MI, Stahlfeld C, Appleman L, Kim JW, Freeman D, Choueiri TK, Spiess PE, Necchi A, Apolo AB, Sonpavde GP. El Zarif T, et al. Among authors: de velasco g. J Natl Cancer Inst. 2023 Dec 6;115(12):1605-1615. doi: 10.1093/jnci/djad155. J Natl Cancer Inst. 2023. PMID: 37563779 Free PMC article.
Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression.
Segovia C, San José-Enériz E, Munera-Maravilla E, Martínez-Fernández M, Garate L, Miranda E, Vilas-Zornoza A, Lodewijk I, Rubio C, Segrelles C, Valcárcel LV, Rabal O, Casares N, Bernardini A, Suarez-Cabrera C, López-Calderón FF, Fortes P, Casado JA, Dueñas M, Villacampa F, Lasarte JJ, Guerrero-Ramos F, de Velasco G, Oyarzabal J, Castellano D, Agirre X, Prósper F, Paramio JM. Segovia C, et al. Among authors: de velasco g. Nat Med. 2019 Jul;25(7):1073-1081. doi: 10.1038/s41591-019-0499-y. Epub 2019 Jul 3. Nat Med. 2019. PMID: 31270502
Clinical Applications of Molecular Biomarkers in Prostate Cancer.
Couñago F, López-Campos F, Díaz-Gavela AA, Almagro E, Fenández-Pascual E, Henríquez I, Lozano R, Linares Espinós E, Gómez-Iturriaga A, de Velasco G, Quintana Franco LM, Rodríguez-Melcón I, López-Torrecilla J, Spratt DE, Guerrero LL, Martínez-Salamanca JI, Del Cerro E. Couñago F, et al. Among authors: de velasco g. Cancers (Basel). 2020 Jun 12;12(6):1550. doi: 10.3390/cancers12061550. Cancers (Basel). 2020. PMID: 32545454 Free PMC article. Review.
Exosomes: Definition, Role in Tumor Development and Clinical Implications.
Carretero-González A, Otero I, Carril-Ajuria L, de Velasco G, Manso L. Carretero-González A, et al. Among authors: de velasco g. Cancer Microenviron. 2018 Jun;11(1):13-21. doi: 10.1007/s12307-018-0211-7. Epub 2018 May 3. Cancer Microenviron. 2018. PMID: 29721824 Free PMC article. Review.
Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial.
Grimm MO, Esteban E, Barthélémy P, Schmidinger M, Busch J, Valderrama BP, Charnley N, Schmitz M, Schumacher U, Leucht K, Foller S, Baretton G, Duran I, de Velasco G, Priou F, Maroto P, Albiges L; TITAN-RCC study group. Grimm MO, et al. Among authors: de velasco g. Lancet Oncol. 2023 Nov;24(11):1252-1265. doi: 10.1016/S1470-2045(23)00449-7. Epub 2023 Oct 13. Lancet Oncol. 2023. PMID: 37844597 Clinical Trial.
111 results